Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1

Conditions

Bites and Stings 2Prostatic Neoplasms 1

Interventions

pembrolizumab 3enzalutamide 2blinatumomab 2abiraterone 2Stents 2Neoadjuvant Therapy 2Immune Checkpoint Inhibitors 2Cytochrome P-450 Enzyme System 2soybean oil, phospholipid emulsion 1durvalumab 1dostarlimab 1cemiplimab 1camrelizumab 1atezolizumab 1Surgical Procedures, Operative 1Surgical Instruments 1Radiotherapy, Conformal 1Radiotherapy 1Passive Cutaneous Anaphylaxis 1Palliative Care 1Nephrotomy 1Nephrostomy, Percutaneous 1N,N-dicyclohexyl-isoborneol-10-sulfonamide 1Morphine 1Lidocaine 1Levobupivacaine 1Immunotherapy 1Hydroxyurea 1Etoposide 1Etanercept 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Bites and Stings × Cytochrome P-450 Enzyme System × Clear all
NCT03792841 2025-10-16

Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC

Amgen

Phase 1 Terminated
212 enrolled
Genitourinary

Bites and Stings, Prostatic Neoplasms

NCT04631601 2025-10-07

Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)

Amgen

Phase 1/2 Terminated
65 enrolled

Bites and Stings

Data powered by HemOnc (CC BY 4.0) Colophon âš¡